BioSpace News Archive

Eargo, Inc., a medical device company on a mission to improve hearing health, announced its support of the new regulatory category of over-the-counter hearing aids, as finalized by the Food and Drug Administration Wednesday, August 17, 2022.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Showcase, taking place virtually.

Cue Health Inc. (“Cue”) (Nasdaq: HLTH) announced today the preprint publication of an independent clinical study - the largest of its kind on asymptomatic people - demonstrating that its point of care (POC) molecular COVID-19 test, which produces results in approximately 20 minutes, is as accurate as a centralized lab-based RT-PCR.

AVITA Medical, Inc. announced that a poster presentation on cell characterization and potential clinical benefits of the RECELL® Autologous Cell Suspension System for the treatment of stable vitiligo will be shared at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting.

Plus Therapeutics, Inc. announced that it was awarded a $17.6 million Product Development Research grant by the Cancer Prevention and Research Institute of Texas to fund the continued development of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome, for the treatment of patients with leptomeningeal metastases.

Accelerate Diagnostics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first healthy volunteer has been successfully dosed in the Phase 1 study of IBI311.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”).

The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data.

Latest Study on “Life Science Tools Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.